Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the first quarter, Holdings Channel.com reports. The institutional investor owned 416,283 shares of the biopharmaceutical company’s stock after selling 13,024 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Gilead Sciences were worth $26,904,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in GILD. BlackRock Inc. grew its holdings in Gilead Sciences by 12.2% during the 1st quarter. BlackRock Inc. now owns 124,723,133 shares of the biopharmaceutical company’s stock valued at $8,060,854,000 after buying an additional 13,539,799 shares during the last quarter. Norges Bank acquired a new stake in Gilead Sciences during the 4th quarter valued at $767,548,000. Dodge & Cox grew its holdings in Gilead Sciences by 35.7% during the 4th quarter. Dodge & Cox now owns 17,107,888 shares of the biopharmaceutical company’s stock valued at $996,706,000 after buying an additional 4,500,035 shares during the last quarter. Parnassus Investments CA grew its holdings in Gilead Sciences by 56.8% during the 1st quarter. Parnassus Investments CA now owns 5,497,761 shares of the biopharmaceutical company’s stock valued at $355,320,000 after buying an additional 1,990,761 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. boosted its holdings in shares of Gilead Sciences by 43.2% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 6,157,567 shares of the biopharmaceutical company’s stock worth $358,717,000 after purchasing an additional 1,858,416 shares during the last quarter. Hedge funds and other institutional investors own 77.18% of the company’s stock.

In other news, Director Richard James Whitley sold 20,282 shares of Gilead Sciences stock in a transaction dated Monday, May 3rd. The stock was sold at an average price of $64.57, for a total transaction of $1,309,608.74. Following the sale, the director now directly owns 51,404 shares of the company’s stock, valued at $3,319,156.28. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.12% of the stock is currently owned by insiders.

Several equities research analysts have recently issued reports on the company. Redburn Partners upgraded Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Tuesday, March 30th. Jefferies Financial Group restated a “buy” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Friday, May 7th. Sanford C. Bernstein upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a report on Thursday, April 1st. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating and set a $69.00 price objective on the stock in a report on Wednesday, May 5th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 30th. Ten equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $99.22.

NASDAQ:GILD opened at $67.18 on Friday. The firm has a 50-day moving average of $66.90. The company has a quick ratio of 1.18, a current ratio of 1.37 and a debt-to-equity ratio of 1.55. Gilead Sciences, Inc. has a 12 month low of $56.56 and a 12 month high of $78.94. The stock has a market capitalization of $84.26 billion, a price-to-earnings ratio of 8.90, a PEG ratio of 0.61 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 29th. The biopharmaceutical company reported $2.08 EPS for the quarter, beating the consensus estimate of $2.06 by $0.02. Gilead Sciences had a return on equity of 51.91% and a net margin of 1.18%. The company had revenue of $6.42 billion for the quarter, compared to analyst estimates of $6.78 billion. On average, research analysts predict that Gilead Sciences, Inc. will post 7.07 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 29th. Stockholders of record on Tuesday, June 15th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 4.23%. The ex-dividend date is Monday, June 14th. Gilead Sciences’s payout ratio is 40.06%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading: VIX – Volatility Index

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.